Nerac

Information That Drives Innovation

We’re here to help with your research needs
+1 860 872 7000
Customer Access
  • Home
  • What We Do
    • Innovation Insights and Consulting Practice
    • Regulatory
    • Medical Device and Life Sciences
    • Technology Scouting and Innovation
    • Market Research
    • Intellectual Property
    • Commercialization Services for TTOs and Start-Ups
    • Critical Updates
  • Who We Serve
  • How to Engage
  • Why Nerac?
  • Meet our Team
    • Leadership Team
    • Our Analysts
    • Our Partners
  • Nerac Insights and Publications
    • Articles
    • Case Studies
    • Press Room
    • Videos
    • Webcasts
    • White Papers
  • Contact Us
You are here: Home / Nerac Insights / Articles / Ebola: Do we need to worry?

Ebola: Do we need to worry?

Facebook3
Google+0
LinkedIn5
Twitter0

By Rebecca Ryznar, Ph.D., Nerac Associate Analyst

Originally published Sep. 2nd, 2014

Zaire Ebola virus (EBOV), the particular Ebola viral strain currently spreading across West Africa, causes the most virulent hemorrhagic fever known to man, and kills up to 90% of those infected. Ebola sets the immune system in overdrive and perturbs clotting mechanisms, causing a victim to bleed to death within an average of a week after contracting the virus. In the early stages of disease, patients initially present with flu-like symptoms, followed by a hemorrhagic phase associated with vomiting of blood, reddening of the eyes, internal and subcutaneous bleeding, eventually leading to organ failure and death.

Want to read the rest of the article? Fill out the form to download: Ebola: Do we need to worry?
Get Download Link

 

 

 

 

Related Posts

  • USA Today: Analyst: NewLink deal a 'boost' for Ebola vaccine
    37
    Our analyst John Leavitt, Ph.D., was recently featured in an article in USA Today. Take a look at it today!   http://www.usatoday.com/story/money/business/2014/11/26/analyst-newlink-deal-boost-ebola-vaccine/19518217/  
    Tags: analyst, article, ph.d, ebola
  • NewLink deal a 'boost' for Ebola vaccine
    36
    "Merck wouldn't have done this if there wasn't very good preliminary results from the clinical trials," said Dr. John Leavitt, a senior biotech analyst with the research firm Nerac. "There must be some trial data that is being shared with Merck by NewLink on the progress of these clinical trials." Read the full Des Moines…
    Tags: read, full, article, analyst, ebola, nerac
  • Killing Them Softly: Making Strides in Green Pesticides for Consumer Use
    33
    By Stephenie Smulligan-Maldanis, M.S., Nerac Analyst, Originally Published: April 19, 2016 Whether we are aware or not, the risks and benefits of pesticide use are part of daily life. As the pesticide market, and the threat of disease continues to grow, so does the concern over the consequences of pesticide use. Increasingly, consumers are skeptical…
    Tags: published, read, originally, disease, analyst, nerac, article, virus
  • Case Studies
  • White Papers
  • Webcasts
  • Articles
    • Nerac Strategist
    • Energy
    • Food & Nutrition
    • Intellectual Property
    • Regulatory
    • Technology & Innovation
    • Medical Device & Healthcare
    • Pharmaceutical
    • Engineering
    • Market Research
    • Critical Alerts
    • Chemistry/Advanced Materials
  • Press Room

Click here to learn more about….

3d printing advanced materials aerospace Ask Kevin Videos biotech CFDA clinical literature evaluations commercialization strategies competitive intelligence conflict minerals Disruptive Technologies emerging markets energy EU MDR FDA food Industry 4.0 innovation Inspiring Next intellectual property intellectual property strategies IP market analysis market research medical device medical devices nerac Nerac client questions Nerac Strategist notified body audit open innovation Order 650 patenting strategies patent landscape pharmaceutical Post-Market Surveillance R&D regulatory regulatory compliance Robert Beinstein Rosemarie Szostak specialty chemicals Sustainable Development Goals technology scouting XcellR8
  • Facebook
  • Google+
  • Linkedin
  • RSS
  • Twitter
  • YouTube
  • Career Opportunities

Copyright © 2021 Nerac · One Technology Drive · Tolland, CT 06084 · 1.860.872.7000

Sign Up for the Nerac Strategist

Like what you see? Sign up here to receive the Nerac Strategist newsletter, a compilation of analyst insights on rapidly developing industry issues, compliance challenges and commercial opportunities!
  • This field is for validation purposes and should be left unchanged.